Share on StockTwits

Sarepta Therapeutics (NASDAQ: SRPT) received a number of price target changes and ratings updates during the last week:

  • Sarepta Therapeutics was upgraded by analysts at Canaccord Genuity from a “hold” rating to a “buy” rating. They now have a $63.00 price target on the stock, up previously from $27.00.
  • Sarepta Therapeutics was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating. They now have a $63.00 price target on the stock.
  • Sarepta Therapeutics was upgraded by analysts at JMP Securities from a “market perform” rating to a “market outperform” rating. They now have a $54.00 price target on the stock.
  • Sarepta Therapeutics was upgraded by analysts at JMP Securities from a “market perform” rating to an “outperform” rating. They now have a $54.00 price target on the stock.
  • Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $52.00 price target on the stock, up previously from $36.00.
  • Sarepta Therapeutics was upgraded by analysts at Citigroup Inc. from a “sell” rating to a “neutral” rating.
  • Sarepta Therapeutics had its price target raised by analysts at Deutsche Bank from $17.00 to $35.00. They now have a “hold” rating on the stock.

Sarepta Therapeutics Inc (NASDAQ:SRPT) opened at 36.70 on Monday. Sarepta Therapeutics Inc has a one year low of $12.12 and a one year high of $55.61. The stock has a 50-day moving average of $26.98 and a 200-day moving average of $26.66. The company’s market cap is $1.386 billion.

Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of rare and infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.